BRAF and colorectal carcinoma: Immune checkpoint inhibitors, such as anti-PD1 antibodies, have shown limited efficacy as a monotherapy in microsatellite-stable BRAF-mutant CRC but may provide benefits when combined with targeted therapies or in tumors exhibiting high Microsatellite Instability [56,57].